The Effects of Helicobacter pylori Eradication on Proteinuria in Patients with Primary Glomerulonephritis

Bahar Caliskan, Halil Yazici, Yasar Caliskan, Yasemin Ozluk, Mine Gulluoglu, Isin Kilicaslan, Aydin Turkmen, Mehmet Sukru Sever, Bahar Caliskan, Halil Yazici, Yasar Caliskan, Yasemin Ozluk, Mine Gulluoglu, Isin Kilicaslan, Aydin Turkmen, Mehmet Sukru Sever

Abstract

Background. Membranous nephropathy (MN) is a common cause of nephrotic syndrome. In most cases it is idiopathic, while it may also be secondary to many diseases. In this study, prevalence of H. pylori infection and the effects of H. pylori eradication on proteinuria levels were investigated. Methods. Thirty five patients with MN (19 male), 12 patients with IgA nephropathy (4 male) and 12 patients with focal segmental glomerulosclerosis (FSGS) (8 male) were studied. The presence of H. pylori antigen was investigated in renal tissues obtained by biopsy, and the effects of H. pylori eradication on proteinuria levels were investigated. Results. Immunohistochemistry with H. pylori antigen revealed no positive staining in the glomeruli of all patients. 19 patients (54%) with MN, 10 (83%) with IgA nephropathy and 4 (33%) with FSGS were positive for H. pylori stool antigen test (P = 0.045). Patients with H. pylori infection were administered eradication therapy (lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days). Before the eradication therapy the mean proteinuria of patients with MN, IgA nephropathy and FSGS were 2.42 ± 3.24 g/day, 2.12 ± 1.63 g/day and 1.80 ± 1.32 g/day, respectively. Three months after eradication, baseline proteinuria levels of patients with MN significantly decreased to 1.26 ± 1.73 g/day (P = 0.031). In all three groups there were no significant differences with regard to serum creatinine, albumin and C-reactive protein levels before and after eradication therapy. Conclusions. The eradication of H. pylori infection may be effective to reduce proteinuria in patients with MN, while spontaneous remission of MN could not be excluded in this patient cohort. This trial is registered with NCT00983034.

References

    1. Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from heymann nephritis to alloimmunization. Journal of the American Society of Nephrology. 2005;16(5):1205–1213.
    1. Burstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. American Journal of Kidney Diseases. 1993;22(1):5–10.
    1. Ronco P, Debiec H. Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men. Seminars in Immunopathology. 2007;29(4):445–458.
    1. Lai KN, Li PKT, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. The New England Journal of Medicine. 1991;324(21):1457–1463.
    1. Jordan SC, Buckingham B, Sakai R, Olson D. Studies of immune-complex glomerulonephritis mediated by human thyroglobulin. The New England Journal of Medicine. 1981;304(20):1212–1215.
    1. Imai H, Hamai K, Komatsuda A, Ohtani H, Miura AB. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney International. 1997;51(1):270–276.
    1. Squarer A, Lemley KV, Ambalavanan S, et al. Mechanisms of progressive glomerular injury in membranous nephropathy. Journal of the American Society of Nephrology. 1998;9(8):1389–1398.
    1. Kerjaschki D. Pathogenetic concepts of membranous glomerulopathy (MGN) Journal of Nephrology. 2000;13(3):S96–S100.
    1. Beck LH, Jr., Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. The New England Journal of Medicine. 2009;361(1):11–21.
    1. Yang A-H, Lin B-S, Kuo K-L, Chang C-C, Ng Y-Y, Yang W-C. The clinicopathological implications of endothelial tubuloreticular inclusions found in glomeruli having histopathology of idiopathic membranous nephropathy. Nephrology Dialysis Transplantation. 2009;24(11):3419–3425.
    1. Nagashima R, Maeda K, Yuda F, Kudo K, Saitoh M, Takahashi T. Helicobacter pylori antigen in the glomeruli of patients with membranous nephropathy. Virchows Archiv. 1997;431(4):235–239.
    1. Moriyama T, Kaneko T, Fujii M, Tsubakihara Y, Kawano S, Imai E. High prevalence of Helicobacter pylori infection in Japanese patients with membranous nephropathy. Alimentary Pharmacology and Therapeutics. 2006;24(4):189–193.
    1. Sugimoto T, Furukawa T, Maeda T, Somura M, Uzu T, Kashiwagi A. Marked reduction of proteinuria after eradication of gastric Helicobacter pylori infection in a patient with membranous nephropathy: coincidental or associated? Internal Medicine. 2007;46(17):1483–1484.
    1. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine. 2009;150(9):604–612.
    1. Van Doorn OJ, Bosman DK, Van’t Hoff BW, Taminiau JA, Ten Kate FJ, Van der Ende A. Helicobacter pylori stool antigen test: a reliable non-invasive test for the diagnosis of helicobacter pylori infection in children. European Journal of Gastroenterology and Hepatology. 2001;13(9):1061–1065.
    1. Tanaka A, Takahashi S. Helicobacter pylori stool antigen test. Nippon Rinsho. 2004;62(3):464–469.
    1. Blanco S, Forné M, Lacoma A, et al. Comparison of stool antigen immunoassay methods for detecting Helicobacter pylori infection before and after eradication treatment. Diagnostic Microbiology and Infectious Disease. 2008;61(2):150–155.
    1. Barratt J, Bailey EM, Buck KS, et al. Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. American Journal of Kidney Diseases. 1999;33(6):1049–1057.
    1. Ko GH, Park HB, Shin MK, et al. Monoclonal antibodies against Helicobacter pylori cross-react with human tissue. Helicobacter. 1997;2(4):210–215.
    1. Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. American Journal of Kidney Diseases. 1995;25(6):862–875.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe